Cramer's take on Valeant

Discussion in 'Valeant Pharmaceuticals' started by anonymous, May 9, 2017 at 12:55 PM.

Tags: Add Tags

  1. anonymous

    anonymous Guest

    Not impressed. Still a sewer.
     
  2. anonymous

    anonymous Guest

    As a reminder:

    "Overall, we understand Valeant's decision to highlight in its press release the EBITDA raise of 1.3% as this is better than the recent trend, although we note to investors that the $50 million raise is relative to approximately $28.88 billion of total debt. Key products and areas such as Xifaxan and B&L continue to underperform.Given that disclosures in the 2016 10-K included material items (such as a disagreement with VRX's Xifaxan licensor Alfa Wasserman), we think waiting for the 10-Q is important. In reality, Valeant's sales are declining, its leverage ratio has increased, and we think its pipeline is weak. We expect the initial investor reaction for the EBITDA guidance will eventually fade upon closer scrutiny."